Figure 3.

CID755673 or CRT 0066101 pretreatment inhibits PKD activation in cerulein-induced experimental pancreatitis. Rats received intraperitoneal (IP) injection of CID755673 (CID, 15 mg/kg) or CRT 0066101 (CRT, 10 mg/kg). Control rats received same volume of vehicle DMSO. After 60 min waiting time, the inhibitor- or vehicle-pretreated animals were given an IP injection of cerulean (CR) or saline (S). The pancreas was collected in 30 min after the cerulein or saline injection. (A) The pancreas tissue lysates were immunoprecipitated with PKD/PKD1 C-20 antibody and PKD1 activity in the immunocomplexes was determined by in vitro kinase assay (IVK). PKD/PKD1 catalytic activities were expressed increased fold over control in the animals injected with saline. Results are means ± SE (n = 3–5) for each condition. ^**p < 0.01 vs. cerulein alone without inhibitor pre-treatments. (B) Western blot was performed to analyze PKD phosphorylation in the tissue lysates using antibodies against phospho-Ser916 PKD, phospho-Ser744/748 PKD. PKD and GAPDH or ERK1/2: for loading controls. Samples were run in a single gel but were not continuous, as indicated by a line between lanes.